Defining the Optimal Treatment Strategy in Patients With Uterine Serous Carcinoma

Area of Science:

• Gynecologic Oncology
• Cancer Treatment Strategies
• Endometrial Cancer Research

Background:

• Uterine serous carcinoma (USC) is an aggressive endometrial cancer subtype with high recurrence and mortality rates.
• The role of adjuvant therapy and the extent of surgical staging in early-stage USC remain subjects of investigation.

Purpose of the Study:

• To evaluate the optimal treatment strategy for women diagnosed with USC.
• To assess the impact of adjuvant treatment and surgical staging on survival and recurrence patterns in USC.

Main Methods:

• Retrospective multicenter study involving 272 women with primary USC in the UK and Netherlands.
• Kaplan-Meier and Cox regression analyses were used to evaluate treatment strategies, overall survival, and progression-free survival.
• Patterns of recurrence were analyzed in relation to primary surgical staging and adjuvant treatment.

Main Results:

• 48% of patients experienced recurrent disease, with a majority having distant recurrence.
• Adjuvant chemotherapy significantly improved overall survival (HR 0.50) and progression-free survival (HR 0.48) in multivariable analysis.
• Even in FIGO stage IA disease, surgical staging alone was associated with a high recurrence rate (42%).

Conclusions:

• Adjuvant chemotherapy offers survival benefits for women with USC across all tumor stages, including early-stage disease.
• The findings challenge the routine use of surgical staging alone for USC, particularly when macroscopic disease is absent.
• Chemotherapy should be strongly considered as part of the adjuvant treatment for USC.